Elan News
Most Popular Elan Story
Bapineuzumab - 15 top blockbuster contenders
The drug: BapineuzumabThe disease: Alzheimer'sThe developers: J&J, Pfizer and ElanPeak projections: $5 billion-$10 billion Once estimated as a potential mega-earner with more than $10 billion in Read more...
Latest Headlines
- October 25, 2011
- October 19, 2011
- February 23, 2011
- January 26, 2011
- August 10, 2010
- April 19, 2010
- December 15, 2009
- August 3, 2009
- June 29, 2009
- June 3, 2009
- May 13, 2009
- April 22, 2009
- April 2, 2009
- March 26, 2009
- February 25, 2009
- January 13, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
